Investigators examine brain tests of patients with COVID-19

patient
Credit: CC0 Public Domain

In a Journal of Neuroimaging analysis of data obtained from 193 patients with COVID-19 who had brain and/or spine imaging and a lumbar puncture because of neurologic symptoms, investigators found that imaging results were related to the presence of SARS-CoV-2 in the cerebrospinal fluid.

The results were called central nervous system hyperintense lesions and leptomeningeal enhancement. Ten percent of with hyperintense lesions in the brain/spine had a positive PCR test result for SARS-CoV-2 in the , compared with no patients without hyperintense lesions in the brain/spine. Twenty-five percent of patients with leptomeningeal enhancement had a positive PCR test result for SARS-CoV-2 in the cerebrospinal fluid, compared with 5% of patients without leptomeningeal enhancement.

"Understanding the relationship between imaging and cerebrospinal fluid findings can improve understanding of neurological symptoms in patients with COVID-19. Although hyperintense lesions in the brain/spine and leptomeningeal enhancement are associated with the presence of SARS-CoV-2 in the cerebrospinal fluid, it is important to recognize that a positive SARS-CoV-2 PCR in the cerebrospinal fluid is uncommon. These imaging findings are predominantly the result of inflammation, hypoxia, or ischemia, rather than infection, of the ," said lead author Ariane Lewis, MD, of NYU Langone Medical Center.

More information: Journal of Neuroimaging, DOI: 10.1111/jon.12880

Provided by Wiley
Citation: Investigators examine brain tests of patients with COVID-19 (2021, June 9) retrieved 6 May 2024 from https://medicalxpress.com/news/2021-06-brain-patients-covid-.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Multi-institutional study looks at brain MRI findings in COVID-19

5 shares

Feedback to editors